Institut de la Màcula accredited as the first Spanish centre for the ECLIPSE-I Fovista (E10030) trial

Rome was the venue for the 4th Euretina Winter Congress last weekend. As well as hosting various talks on retinal pathologies, the event included the Investigator Meeting of Ophthotech, which was attended by Dr. Jordi Monés, the Director and Ophthalmologist of the Institut de la Màcula, together with Dr. Hussein Al Muhtaseb.

At the Meeting, Dr. Samir Patel, the President and CEO of Ophthotech Corporation, accredited the Institut de la Màcula as the first Spanish centre to work on the ECLIPSE-I Fovista (E10030) trial.

Dr. Patel said the trial could herald a new era of combined treatment (anti-PDGF + anti-VEGF) and drew attention to the progress it could mean for treating exudative Age-Related Macular Degeneration (AMD) compared to what is currently on offer.

ECLIPSE-I Fovista (E10030) is a phase III, randomised, double-blind, controlled clinical trial that establishes the efficacy and safety of intravitreous injections of FOVISTA, an inhibitor of platelet-derived growth factor (anti-PDGF). FOVISTA is administered in combination with Lucentis® (anti-VEGF) in order to study its efficacy, together with the present anti-VEGF monotherapy.